A Phase 3 trial in 2013 (NCT01970098) found that the TRH derivative rovatirelin (KPS-0373) improved severe ataxia in SCA31 and SCA6 patients and that these effects were more prominent than in patients with less severe ataxia [18]. The gene discussed is TRH; the disease is Ataxia.